

## Research Article



# Isolation and Complete Capsid Sequence of Enterovirus D111 from Faeces of a Child with Acute Flaccid Paralysis in Nigeria

Faleye Temitope Oluwasegun Cephas<sup>1,2\*</sup>, Adewumi Moses Olubusuyi<sup>1</sup>, Olayinka Olaitan Titilola<sup>3</sup> and Adeniji Johnson Adekunle<sup>1,3</sup>

<sup>1</sup>Department of Virology, University of Ibadan, Ibadan, Oyo State, Nigeria; <sup>2</sup>Center for Human Virology and Genomics, Department of Microbiology, Nigerian Institute of Medical Research, Lagos, Nigeria; <sup>3</sup>WHO National Poliovirus Laboratory, University of Ibadan, Ibadan, Oyo State, Nigeria.

**Abstract** | The WHO recommended cell-culture-based algorithm requires enterovirus (EV) isolates to produce reproducible cytopathic effect (R-CPE) in RD and/or L20b cell lines. Samples with non-reproducible CPE (NR-CPE) are considered negative for EVs. We investigated whether there could be EVs lurking in samples with NR-CPE. Fifty-nine cell culture supernatants (CCS) (collected between 2016 and 2017) from RD and L20b cell-culture-tubes with NR-CPE, were analyzed. The tubes had been previously inoculated with stool suspension from children (<15 years) in Nigeria with acute flaccid paralysis (AFP). All CCS were screened for Enteric Adenoviruses (EAVs) and group A Rotavirus (GARV) using a rapid immunochromatographic test kit. Subsequently, they were passaged in HEP-2 cell line. All isolates were subjected to RNA extraction, cDNA synthesis, three (5'-UTR, VP1 and EV Species C [EV-C]) different PCR assays and sequencing of amplicons. EVs were further subjected to [']Illumina sequencing. All CCS were negative for EAVs and GARVs. Four CCS produced R-CPE in HEP-2 cell line, three of which were positive for the 5'-UTR assay. Of the three isolates, two and none were positive for the VP1 and EV-C assays, respectively. One of the two VP1 amplicons was successfully sequenced and identified as Echovirus 1. Illumina sequencing of the three 5'-UTR positive isolates confirmed the E1 isolate and typed the remaining two as EV-Ds (94 and 111). We describe the first EV-D isolates of Nigerian origin and the first complete capsid sequence of the virus globally. We also show that NR-CPE could sometimes be caused by EVs that do not produce R-CPE in specific cell lines.

**Received** | July 08, 2019; **Accepted** | August 20, 2019; **Published** | August 29, 2019

**\*Correspondence** | Faleye Temitope Oluwasegun Cephas, Department of Virology, University of Ibadan, Ibadan, Oyo State, Nigeria; **Email:** faleyetemitope@gmail.com

**DOI** | <http://dx.doi.org/10.17582/journal.hv/2019/6.4.85.92>

**Citation** | Cephas, F.T.O., A.M. Olubusuyi, O.O. Titilola and A.J. Adekunle. 2019. Isolation and complete capsid sequence of enterovirus D111 from faeces of a child with acute flaccid paralysis in Nigeria. *Hosts and Viruses*, 6(4): 85-92.

**Keywords:** Acute flaccid paralysis, HEP-2, EV-D111, Enteroviruses, Nigeria

## Introduction

There are 15 Species in the genus *Enterovirus*, family *Picornaviridae*, order *Picornavirales* (<http://www.picornaviridae.com/enterovirus/enterovirus.htm>). Enterovirus Species C (EV-C) remains the type Species and Poliovirus (PV), the prototype member of the genus. Enteroviruses (EVs)

have a naked capsid with icosahedral symmetry and a diameter of 28-30nm. The capsid encapsulates a positive sense, single-stranded RNA genome that is 7,500 nucleotides in length. The genome has one open reading frame (ORF) that is flanked by untranslated regions on both ends. The ORF encodes one polyprotein that is auto catalytically cleaved to make 11 proteins; four structural proteins

(VP1 – VP4) and seven non-structural proteins (2A-2C and 3A-3D). Classically, EV identification was done by neutralization assays. However, since a correlation was shown to exist between serological types and VP1 sequence (Oberste et al., 1999), VP1 amplification and sequencing became the standard for EV identification. Recently, the European Non-polio Enterovirus Network (ENPEN) recommended (Harvala et al., 2018) that in cases where VP1 data (or the full genome) is not available, VP2 and VP4 can be utilized for EV identification.

Most of the EV data available globally is courtesy the Global Polio Laboratory Network (GPLN); the laboratory arm of the Global Polio Eradication Initiative (GPEI). GPEI was established to eradicate PV globally and have so far reduced the incidence of poliomyelitis by >99.9% (Kew and Pallansch, 2018). Their approach has so far included a blend of surveillance for PV (in acute flaccid paralysis [AFP] cases as well as in the environment) and vaccination (using both inactivated and live attenuated poliovirus vaccines) to interrupt PV transmission chains (Kew and Pallansch, 2018).


In the GPLN, PV detection is done using a cell culture-based algorithm that requires PV isolates to produce reproducible cytopathic effect (R-CPE) in RD and L20b cell lines (WHO, 2003, 2004, 2015). The algorithm also results in the isolation of non-polio enteroviruses (NPEVs) which are also required to produce R-CPE in RD and/or L20b cell lines (WHO, 2003, 2004, 2015). Samples with non-reproducible CPE (NR-CPE) are considered negative for EVs. This phenomenon of NR-CPE has been suggested to be caused by nonspecific cytotoxicity, Adenovirus or Reoviruses (to which the Rotaviruses belong) (WHO, 2011). However, we (Adeniji et al., 2018) recently showed that EVs could also contribute to NR-CPE. In this study, we go a step further to find out how often the three (Adenoviruses, group A Rotaviruses and EVs) virus types are present in cell culture supernatants (CCS) recovered from L20b cell culture tubes with NR-CPE.

## Materials and Methods

### Samples

Fifty-nine (59) cell culture supernatants (CCS) were analyzed in this study following the algorithm depicted in Figure 1. All 59 CCS were recovered from

L20b cell culture tubes with NR-CPE. The tubes had been previously inoculated with stool suspension from children ( $\leq 15$  years old) in Nigeria with acute flaccid paralysis (AFP). Prior this study, the samples were accumulated over the course of one (1) year (2016-2017) during which they were stored at  $-20^{\circ}\text{C}$ .



**Figure 1:** A schematic representation of the algorithm followed in this study.

### Adenovirus and group a rotavirus screen

A rapid immunochromatographic test kit (Rotavirus Group A antigen/Enteric Adenovirus Antigen Rapid test kit, Accumed Technology Co. Ltd, Beijing) was used to screen the samples for Enteric Adenoviruses and Group a Rotavirus. As controls, a fecal suspension from a child with Rotavirus diarrhea that we had confirmed by molecular testing (unpublished data) and reference Adenovirus 1 and 6 from the BBSRC (a kind gift from Oladipo K.E.) were used as positive controls.

### Passage in Hep2 cell line

The HEP-2 cell line used in this study was maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 2% Fetal Calf Serum, 100IU/ml penicillin and 100mg/ml streptomycin. All CCS were passaged in HEP-2 cell line and incubated for 14 days at  $37^{\circ}\text{C}$ . For each CCS,  $200\mu\text{L}$  was inoculated into two tissue culture tubes each containing HEP-2 cells. The tubes were then incubated at  $37^{\circ}\text{C}$  and monitored for 14 days. Daily the tubes were visually screened (using an inverted microscope) for EV characteristic cytopathic effect (CPE). Tubes in which CPE was observed were further passaged to confirm such. Samples were only declared negative for CPE if none was observed after 14 days of observation.

**Table 1:** Details of PCR assays.

S/N	Assay name	Primer name	Region amplified	Amplicon size (bp)	Extension time (Seconds)	cDNA used	Reference
1	PE-5-UTR	PanEnt-5'-UTR-F PanEnt-5'-UTR-R	5'-UTR	~114	30	1	Adeniji and Faleye, 2014
2	EC 3Dpol/3'-UTR PCR	HEV-C-3D HEV-C-3'-UTR	3Dpol-3'-UTR	~429	30	1	Adeniji and Faleye, 2014
3	*PE-VP1a	224 222	VP3-VP1	~750	60	2	Nix et al., 2006
4	*PE-VP1b	AN89 AN88	VP1	~350	30	NA	Nix et al., 2006

NA: Not Applicable; \*Both PE-VP1a and PE-VP1b are both components of the Nix et al., 2006 semi-nested PCR protocol. PE-VP1a is the first round while PE-VP1b is the second round PCR; cDNA 1= synthesized using random hexamers (Faleye et al., 2017); cDNA 2= synthesized using Oligos AN32-AN35 (Nix et al., 2006).

*Total RNA extraction and cDNA synthesis*

Total RNA was extracted from all samples that produced CPE in HEp-2 cell line using the Total RNA extraction kit (Jena Bioscience, Jena, Germany). RNA was extracted following the guidelines detailed by the manufacturer. The SCRIPT cDNA synthesis kit (Jena Bioscience, Jena, Germany) was used for cDNA synthesis following manufacturer's instructions. Two different cDNAs were prepared; cDNA 1 (using random hexamers, (Faleye et al., 2018)) and cDNA 2 (using primers AN32 to AN35, (Nix et al., 2006)).

*Polymerase Chain Reaction (PCR) assays*

Three (PE-5-UTR, EC 3Dpol/3'-UTR PCR and PE-VP1) different PCR assays that target three different (5'-UTR, 3Dpol-3'-UTR and VP1) EV genomic regions were done in this study (Table 1). It is however crucial to mention that the VP1 assay is a semi-nested PCR assay with PE-VP1a and PE-VP1b being the first and second round assays, respectively.

All primers used were made in 100µM concentrations. All PCR assays were done in 30µL volumes containing 6µL of Red Load PCR mix (Jena Bioscience, Jena, Germany), 0.3 µL of each of the forward and reverse primers, 5µL of cDNA or first round PCR product and 18.4µL of PCR grade water. Amplification was done using the Veriti thermal cycler as follows; 94°C for 3 min followed by 45 cycles of 94°C for 30s, 42°C for 30s and 60°C for 30s with ramp from 42°C to 60°C adjusted to 40%. This was followed by 72°C for 7 min and held at 4°C till terminated. It should however be noted that the extension temperature varied based on the expected amplicon size as detailed in Table 1. All PCR products were resolved on 2% agarose gels

stained with ethidium bromide and viewed using a transilluminator.

*Sanger sequencing*

Only the amplicons generated by the PE-VP1b assay (Table 1) were subjected to Sanger sequencing. The amplicons were shipped to Macrogen Inc, Seoul, South-Korea, where gel extraction and Sanger sequencing were done. Sanger sequencing was done using the primers AN89 and AN88.

*Illumina sequencing*

For Illumina Sequencing, cDNA 1 was used. The genomes were amplified in overlapping fragments of 2 – 3kb as previously described (Faleye et al., 2018). Irrespective of the intensity of amplicon or whether or not there were amplicons, for each isolate, the overlapping genomic fragments were pooled and shipped to a commercial facility (MR DNA, Texas, USA) where library preparation (Nextera DNA sample preparation kit), Illumina sequencing (paired end, 300 cycles, HiSeq) were done. The Illumina sequencing data was assembled using the Kiki assembler v0.0.9. Subsequently, detection of EV contigs was done using the Enterovirus Genotyping Tool (EGT) v1.0 (Kroneman et al., 2011).

*Enterovirus identification and Nucleotide accession numbers*

Enterovirus types were determined using the EGT v1.0 (Kroneman et al., 2011). Nucleotide sequences generated in this study have been submitted to GenBank under the accession numbers MK190417- MK190420.

*Phylogenetic analysis*

All the sequences of the EV types of interest in GenBank were downloaded. Using the EGT v1.0 (Kroneman et al., 2011), sequences that did not cover the VP1 region of interest were removed. The sequences were then aligned using the Clustal W program in MEGA 5 software with default settings (Tamura et al., 2011). Subsequently, neighbor-joining trees were constructed using 1000 bootstrap replicates (Tamura et al., 2011). The accession numbers of sequences retrieved from GenBank for analysis are shown in the phylograms.

**Results and Discussion**

*Adenovirus and group a rotavirus screen*

All the samples screened in this study were negative for the Enteric Adenovirus and Group a Rotavirus Screen (Figure 1). However, the positive controls (a fecal suspension from a child with Rotavirus diarrhea and reference Adenovirus 1 and 6) were repeatedly and consistently detected by the rapid detection kit.

*Passage in HEP2 cell line*

On passage in HEP2 cell line, only 4 (6.8%) of the 59 samples yielded isolates that were reproducible on passage in HEP2 cell line (Figure 1).

*PCR assays*

Three (75%) of the four isolates were positive for the Pan Enterovirus 5-UTR (PE-5-UTR) assay. None of the three (3) PE-5-UTR positive isolates was positive for the Enterovirus Species C detection/resolution (EC 3Dpol/3<sup>1</sup>-UTR PCR) assay. Two (2) of the three (66.7%) PE-5-UTR positive isolates were positive for the Pan Enterovirus VP1 (PE-VP1) assay (Figure 1).

*Sanger sequencing*

Of the two (2) samples positive for the PE-VP1 and shipped to the sequencing facility, only one was successfully sequenced. The other could not be sequenced due to insufficient volume. The sequenced isolate was typed as Echovirus 1 using the EGT (Table 2).

*Illumina sequencing*

This showed that isolates 1, 2 and 3 contained EV-D94, E1 and EV-D111 (Table 2). One contig spanning the entire capsid region was assembled for each of isolates 2 and 3 (Figure 2). On the other hand, two contigs were assembled for isolate 1. One each

within the capsid (P1) and nonstructural protein (P3) encoding genomic regions (Figure 2).

**Enterovirus Genotyping Tool Results**  
You may bookmark this page to revisit results of this job (643848238) later.

Name	Length	Family Genus Species	BLAST score	Genotype, genome	VP1 Serotype, Sub-Genogroup	Report	Genome
Isolate_1a_MK190417_EVD94	1165	Picornaviridae Enterovirus D	86.09389	Could not assign		<a href="#">Report</a>	
Isolate_1b_MK190420_EVD94	1230	Picornaviridae Enterovirus D	89.42623	EV-D94		<a href="#">Report</a>	
Isolate_2_MK190418_E1	3815	Picornaviridae Enterovirus B	78.68809	E-1	E-1	<a href="#">Report</a>	
Isolate_3_MK190419_EVD111	5208	Picornaviridae Enterovirus D	79.42079	Could not assign	EV-D111	<a href="#">Report</a>	

**Figure 2:** The Contigs assembled from the Illumina sequencing data generated for the three PE-5UTR positive isolates. The contigs and the genomic regions covered are displayed using the EGT.

*A glitch in the enterovirus genotyping tool*

It was observed that for isolate 3 (Table 2), there was disparity in the genotype and serotype as determined by the EGT (Figure 2). To resolve this aberration and confirm the identity of isolate 3, nucleotide similarity between the VP1 sequence of isolate 3 (and other EV-D111 from GenBank) and a reference EV-D70 was estimated (Table 3). This confirmed that isolate 3 was indeed EV-D111. Furthermore, using the EGT to type the six (6) EV-D111 VP1 sequences available in GenBank, prior this study, showed that the aberration was not unique to isolate 3 (Figure 3).


Name	Length	Family Genus Species	BLAST score	Genotype, genome	VP1 Serotype, Sub-Genogroup	Report	Genome
1 JN255685_EVD111_CAF-0UP_05-059	295	Picornaviridae Enterovirus D	73.037544	EV-D70	EV-D111	<a href="#">Report</a>	
2 JN255694_EVD111_CAF-NG8_06-107	295	Picornaviridae Enterovirus D	73.22034	EV-D70	EV-D111	<a href="#">Report</a>	
3 JN255683_EVD111_CAF-BAN_06-150	295	Picornaviridae Enterovirus D	73.037544	EV-D70	EV-D111	<a href="#">Report</a>	
4 EVD111_NGR_2017	295	Picornaviridae Enterovirus D	73.46539	EV-D70	EV-D111	<a href="#">Report</a>	
5 JX431302_EVD111_111_TOK_230_HC	295	Picornaviridae Enterovirus D	75.17007	EV-D70	EV-D111	<a href="#">Report</a>	
6 JF416935_EVD111_KH2640_Chimpan	295	Picornaviridae Enterovirus D	73.12926	EV-D70	EV-D111	<a href="#">Report</a>	
7 EF127249_EVD111_17-04_DRC_2000	295	Picornaviridae Enterovirus D	73.61111	EV-D70	EV-D111	<a href="#">Report</a>	
8 D00820_EVD70_A70_71	295	Picornaviridae Enterovirus D	100.0	EV-D70	EV-D70	<a href="#">Report</a>	

**Figure 3:** All the EV-D111 sequences in GenBank described till date alongside a reference EV-D70 and the EGT identification glitch.


*Phylogenetic analysis*

Considering EVDs are being described for the first time in the country, it was subjected to phylogenetic analysis and the data showed that two (1 and 2) lineages of EV-D111 have been documented globally (Figure 4). The EV-D111 lineage described in this study belongs to lineage 1 alongside those recovered

in Cameroon and Central Africa Republic (CAF) (Figure 4). It is crucial to mention that, prior this study, only six (6) EV-D111 sequences have been described till date and all were detected in sub-Saharan Africa (Figure 5).



**Figure 4:** Phylogram of partial VP1 sequences of EV-D111. The phylogenetic tree is based on an alignment of partial EV-D111 VP1 sequences available in GenBank and the one described in this study. The EV-D111 described in this study is indicated with a black triangle. Bootstrap values are indicated if >50%.



**Figure 5:** Global distribution of EV-D111 detection sources. It is crucial to note that, till date, all have been detected in sub-Saharan Africa.

In this study we screened 59 CCSs with NR-CPE for Enteric Adenovirus or Group a Rotavirus and found them to be negative. Though, it is currently impossible to assay for nonspecific cytotoxicity and several other non-Enteric Adenoviruses and Reoviruses (asides the Group a Rotaviruses) remain unaccounted for in this study, the results suggest that cases of NR-CPE might not always be accounted for by Enteric Adenoviruses or Group A Rotaviruses.

We (Adeniji et al., 2018) had previously shown that EVs could be recovered from CCSs of NR-CPE by

direct RT-snpPCR (Nix et al., 2006; WHO, 2015). We (Adeniji et al., 2018) also showed that EVs were detectable by direct RT-snpPCR in 30.8% (4/13; 2 each of EV-Cs and EV-Bs) of the CCSs. We have taken a step further to recover the EV-B and EV-C isolates on RD (Adeniji et al., 2018) and Hep-2 (Faleye et al., 2019) cell lines, respectively. Considering, Hep-2 cell line supports replication of EV-Bs and has been documented to be better than RD in supporting the replication EV-Cs (Sadeuh-Mba et al., 2013), we selected it for use in this study. Using Hep-2 cell line, we recovered four (4) isolates from the samples screened and showed unequivocally, that three of them were EVs. Of the EVs detected in this study, one (E1) belongs to EV-B while the remaining two are members of EV-D (EV-D111 and EV-D94). To our surprise, none of the isolates recovered were EV-C members despite the documented predilection of Hep-2 cell lines for EV-Cs (Sadeuh-Mba et al., 2013) and our previous findings of EV diversity in NR-CPE (Adeniji et al., 2018).

Specifically, 5% (3/59) of the NR-CPE CCSs screened in this study had EVs that were missed by the RD-L20b (R-L) cell-culture-based algorithm (WHO, 2003, 2004, 2015). We therefore confirm in this study that NR-CPE could sometimes be caused by EVs that possibly do not produce R-CPE in RD and L20b cell lines but do so in other cell lines like HEp-2. How often these EVs cause NR-CPE in R-L cell lines need further investigation. However, pending that, it seems 5% (this study) to 30% (Adeniji et al., 2018) of CCSs from NR-CPE on R-L cell lines might contain EVs.

Three EVs (E1, EV-D111 and EV-D94) were identified in this study. While VP1 data was available to identify E1 and EV-D111, the EV-D94 isolate had no VP1 data available (Figure 2). It has been recommended (Harvala et al., 2018) and we have found it to be true (Adewumi et al., 2018) that in cases where VP1 data is not available, VP2 and VP4 can be utilized for EV identification. Hence, identification of the EV-D94 was done using a combination of the EGT and BLASTn result (data not shown). While the BLASTn result (data not shown) identified the isolate as EV-D94, the EGT could not assign it to any EV type using the VP2 and VP4 data. It however identified the isolate as EV-D94 using sequence data from the P3 genomic region, confirming the BLASTn result for the same region.

**Table 2:** Identity of PE-5UTR positive samples using VP1 Sanger and Illumina data.

EV Isolate S/N	PE-VP1 Assay	Identity		EV Species
		Sanger	Illumina	
1	Positive	Not Sequenced	EV-D94	EV-D
2	Positive	Echovirus 1	Echovirus 1	EV-B
3	Negative	Not Applicable	EV-D111	EV-D

**Table 3:** Estimation of similarity between EV-D111 and EV-D70 VP1 to confirm identity of Isolate 3.

EV-D111	Reference EV-D70	Distance (%)	Similarity (%)
JX431302 EVD111 111 TOK-230 HC 2008	D00820 EVD70 J670 71	31.03	68.97
JN255684 EVD111 CAF-NGB-06-107 2006	D00820 EVD70 J670 71	32.15	67.85
EF127249 EVD111 17-04 DRC 2000	D00820 EVD70 J670 71	33.27	66.73
EVD111 NGR 2017	D00820 EVD70 J670 71	33.89	66.11
JF416935 EVD111 KK2640 Chimpanzee NHP 2011	D00820 EVD70 J670 71	33.94	66.06
JN255683 EVD111 CAF-BAN-06-150 2006	D00820 EVD70 J670 71	34.52	65.48
JN255685 EVD111 CAF-OUP-05-059 2005	D00820 EVD70 J670 71	34.58	65.42

The EV-D94 and EV-D111 described in this study (Table 2) are being described for the first time in Nigeria. In fact, should the information in GenBank and the Picornavirus Study Group website be real-time, as at the 4<sup>th</sup> of November 2018 ([http://www.picornaviridae.com/enterovirus/ev-d/ev-d\\_seq.htm](http://www.picornaviridae.com/enterovirus/ev-d/ev-d_seq.htm)), no complete genome of EV-D111 has been described and complete sequences exist for only the VP1 and VP4 genes. The EV-D111 sequence data we provide here, has the complete VP4, VP2, VP3, VP1, 2A, 2B, 2C, 3A and 3B genes (Figure 2). It also has partial sequences for 5-UTR and 3C (Figure 2). Hence, some of the sequence data we provide for EV-D111 are being described for the first time globally. It is however, crucial to note that this valuable data would have been missed if the CCSs from these NR-CPEs had not been re-screened. We believe, that as the EV community move more towards direct detection of EVs from samples using RT-PCR and NextGen sequencing strategies (Isaacs et al., 2018; Joffret et al., 2018; Majumdar et al., 2018), it is likely that we have less of these omissions. However, as we have previously shown (Adeniji et al., 2017), it should be noted that RT-PCR assays have limit of detection and their sensitivity can be enhanced when augmented with cell culture.

To the best of our knowledge, till date, EV-D111 has only been detected in sub-Saharan Africa (Junttila et al., 2007; Harvala et al., 2011; Bessaud et al., 2012; Sadeuh-Mba et al., 2013). Why this is the case is not clear. It therefore remains to be shown whether

EV-D111 is present or circulating outside sub-Saharan Africa. Pending that, it seems EV-D111 is confined to the region (Figure 5). Though confined to sub-Saharan Africa, EV-D111 has been recovered from faeces of NHPs (Harvala et al., 2011), healthy children (Sadeuh-Mba et al., 2013) and those with AFP (Bessaud et al., 2012; Junttila et al., 2007 and this study). Hence, its zoonotic potential is clear. More importantly, the strain found in the AFP case in Nigeria (this study, Figure 4) belongs to lineage 1; the same lineage to which that found in NHP in Cameroon (a country sharing border with Nigeria) belongs. Considering the global distribution of EV-D68 (another member of EV species D) and its recurrent association with outbreaks with severe clinical manifestations (Esposito et al., 2015; Knoester et al., 2018), it is essential that the molecular epidemiology of this EV type be better investigated.

### Acknowledgements

We thank the WHO National Polio Laboratory in Ibadan, Nigeria for providing the HEP-2 cell line and anonymous cell culture supernatants analyzed in this study. We thank Oladipo Kolawole Elijah for providing us reference Adenovirus 1 and 6 from BBSRC. This study was partly funded by a TET Fund grant to Adeniji J.A. PhD.

### Author's Contribution

FTOC, AMO, OOT and AJA study design. OOT

sample collection. FTOC and AMO laboratory analysis. FTOC, AMO, OOT, AJA reagent contribution. FTOC wrote the first draft of the manuscript. FTOC, AMO, OOT, AJA edited the manuscript. FTOC, AMO, OOT, AJA read and approved the final draft of the manuscript. AMO and AJA supervision. AJA funding.

### Statement of conflict of interests

The authors declare that no conflict of interests exist. In addition, no information that can be used to associate the isolates analyzed in this study to any individual is included in this manuscript.

## References

- Adeniji, J.A. and T.O.C. Faleye. 2014. Impact of cell lines included in enterovirus isolation protocol on perception of nonpolio enterovirus species C diversity. *J. Virol. Methods.* 207: 238-247. <https://doi.org/10.1016/j.jviromet.2014.07.016>
- Adeniji, J.A., F.A. Ayeni, A. Ibrahim, K.A. Tijani, T.O.C. Faleye and M.O. Adewumi. 2017. Comparison of algorithms for the detection of enteroviruses in stool specimens from children diagnosed with Acute Flaccid Paralysis. *J. Pathog.* Volume 2017; Article ID 9256056, 9 pages. <https://doi.org/10.1155/2017/9256056>
- Adeniji, J.A., U.I. Ibok, O.T. Ayinde, A.O. Oragwa, U.E. George, T.O.C. Faleye and M.O. Adewumi. 2018. Nonpolio enteroviruses can also be recovered from non-reproducible cytopathology in L20B cell line. *J. Adv. Microbiol.* 9(4): 1-10. <https://doi.org/10.9734/JAMB/2018/40046>
- Adewumi, M.O., T.O.C. Faleye, C.O. Okeowo, A.M. Oladapo, J. Oyathelemhi, O.A. Olaniyi, O.C. Isola, J.A. Adeniji. 2018. Identification of previously untypable RD cell line isolates and detection of EV-A71 genotype C1 in a child with AFP in Nigeria. *Pathog. Glob. Health.* 26: 1-7. <https://doi.org/10.1101/334094>
- Bessaud, M.1., S. Pillet, W. Ibrahim, M.L. Joffret, B. Pozzetto, F. Delpeyroux and I. Gouandjika-Vasilache. 2012. Molecular characterization of human enteroviruses in the Central African Republic: uncovering wide diversity and identification of a new human enterovirus A71 genogroup. *J. Clin. Microbiol.* 50(5):1650-1658. <https://doi.org/10.1128/JCM.06657-11>
- Esposito, S., S. Bosis, H. Niesters and N. Principi. 2015. Enterovirus D68 infection. *Viruses.* 7(11): 6043-6050. <https://doi.org/10.3390/v7112925>
- Faleye, T.O.C., M.O. Adewumi, M.O. Japhet, O.M. David, A.O. Oluyeye, J.A. Adeniji and O. Famurewa. 2017. Non-polio enteroviruses in faeces of children diagnosed with acute flaccid paralysis in Nigeria. *BMC Virol. J.* 14: 175. <https://doi.org/10.1186/s12985-017-0846-x>
- Faleye, T.O.C., M.O. Adewumi and J.A. Adeniji. 2018. Reference echovirus 7 and 19 genomes from Nigeria. *Microbiol. Resour. Announc.* 7(22): e01465-18. <https://doi.org/10.1128/MRA.01465-18>
- Faleye, T.O.C., M.O. Adewumi, O.T. Olayinka and J.A. Adeniji. 2019. Characterization of a Coxsackievirus A20 genome from a child with acute flaccid paralysis in Nigeria. *Microbiol. Resour. Announcement.* Accepted 6th September 2019. In press. <https://doi.org/10.1101/399212>
- Harvala, H., C.P. Sharp, E.M. Ngole, E. Delaporte, M. Peeters and P. Simmonds. 2011. Detection and genetic characterization of enteroviruses circulating among wild populations of chimpanzees in cameroon: relationship with human and simian enteroviruses. *J. Virol.* 85 (9): 4480-4486. <https://doi.org/10.1128/JVI.02285-10>
- Harvala, H., E. Broberg, K. Benschop, 2018. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. *J. Clin. Virol.* 101:11-17. <http://www.picornaviridae.com/enterovirus/enterovirus.htm> Last accessed on the 8<sup>th</sup> of September 2019. [http://www.picornaviridae.com/enterovirus/ev-d/ev-d\\_seq.htm](http://www.picornaviridae.com/enterovirus/ev-d/ev-d_seq.htm) Last accessed on the 8<sup>th</sup> of September 2019.
- Isaacs, S.R., K.W. Kim, J.X. Cheng, R.A. Bull, S. Stelzer-Braid, F. Luciani, W.D. Rawlinson and M.E. Craig. 2018. Amplification and next generation sequencing of near full-length human enteroviruses for identification and characterisation from clinical samples. *Sci. Rep.* 8(1):11889. <https://doi.org/10.1038/s41598-018-30322-y>
- Joffret, M.L., P.M. Polston, R. Razafindratsimandresy, M. Bessaud, J.M. Heraud and F. Delpeyroux. 2018. Whole genome sequencing of enteroviruses species A to D by high-throughput sequencing: Application for viral mixtures. *Front Microbiol.* 9: 2339. <https://doi.org/10.3389/fmicb.2018.02339>

- Junttila, N., N. Lévêque, J.P. Kabue, G. Cartet, F. Mushiya, J.J. Muyembe-Tamfum, A. Trompette, B. Lina, L.O. Magnius, J.J. Chomel and H. Norder. 2007. New enteroviruses, EV-93 and EV-94, associated with acute flaccid paralysis in the Democratic Republic of the Congo. *J. Med. Virol.* 79(4): 393-400. <https://doi.org/10.1002/jmv.20825>
- Kew, O. and M. Pallansch. 2018. Breaking the last chains of poliovirus transmission: Progress and challenges in global polio eradication. *Annu. Rev. Virol.* 5(1): 427-451. <https://doi.org/10.1146/annurev-virology-101416-041749>
- Knoester, M., J. Helfferich, R. Poelman, C.V. Leer-Buter, O.F. Brouwer and H.G.M. Niesters. 2016. EV-D68 AFM working group. 2018. Twenty-Nine cases of enterovirus-D68 associated acute flaccid myelitis in Europe 2016; A case series and epidemiologic overview. *Pediatr. Infect. Dis. J.* <https://doi.org/10.1097/INF.0000000000002188>
- Kroneman, A., H. Vennema, K. Deforche, *et al.*, 2011. An automated genotyping tool for enteroviruses and noroviruses. *J. Clin. Virol.* 51: 121-125. <https://doi.org/10.1016/j.jcv.2011.03.006>
- Majumdar, M. and J. Martin. 2018. Detection by direct next generation sequencing analysis of emerging enterovirus D68 and C109 strains in an environmental sample from Scotland. *Front. Microbiol.* 9: 1956. <https://doi.org/10.3389/fmicb.2018.01956>
- Nix, W.A., M.S. Oberste and M.A. Pallansch. 2006. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. *J. Clin. Microbiol.* 44(8): 2698-2704. <https://doi.org/10.1128/JCM.00542-06>
- Oberste, M.S., K. Maher, D.R. Kilpatrick, *et al.*, 1999. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. *J. Virol.* 73(3): 1941-1948.
- Sadeuh-Mba, S.A., M. Bessaud, D. Massenet, M.L. Joffret, M.C. Endegue, R. Njouom, J.M. Reynes, D. Rousset and F. Delpeyroux. 2013. High frequency and diversity of species C enteroviruses in Cameroon and neighboring countries. *J. Clin. Microbiol.* 51(3): 759-770. <https://doi.org/10.1128/JCM.02119-12>
- Tamura, K., D. Peterson, N. Peterson, *et al.*, 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol. Biol. Evol.* 28(10): 2731-2739. <https://doi.org/10.1093/molbev/msr121>
- WHO. 2011. Supplement to the WHO polio laboratory manual. An alternative test algorithm for poliovirus isolation and characterization; 2011. Available: [http://apps.who.int/immunization\\_monitoring/Supplement\\_polio\\_lab\\_manual.pdf](http://apps.who.int/immunization_monitoring/Supplement_polio_lab_manual.pdf). Last accessed 23rd June 2017.
- WHO. 2003. Guidelines for environmental surveillance of poliovirus circulation, Geneva, Switzerland.
- WHO. 2004. Polio laboratory manual. Geneva, Switzerland, 4<sup>th</sup> Edition.
- WHO. 2015. Enterovirus surveillance guidelines: Guidelines for enterovirus surveillance in support of the Polio Eradication Initiative, Geneva, Switzerland.